Luo Axis Co., Ltd. submits IPO registration to the GEM, mainly engaged in the research and development, production, and sales of bearings and related components.
According to the prospectus, Lube Bearing Co., Ltd. is one of the largest comprehensive bearing manufacturing enterprises in China, specializing in the research and development, production, and sales of bearings and related components.
On May 20, Luoyang Bearing Group Co., Ltd. (referred to as Luozhou) applied for a change in the status of its IPO review on the ChiNext Board of the Shenzhen Stock Exchange to "submit registration." China Securities Co., Ltd. is its sponsor, and it plans to raise 1.8 billion yuan.
According to the prospectus, Luozhou mainly engages in the research, development, production, and sales of bearings and related components, and is one of the largest comprehensive bearing manufacturing enterprises in China. The company has been deeply involved in the bearing industry for many years, with outstanding technological innovation capabilities, and has the only national key laboratory in the bearing industry, leading in research and layout in the high-end bearing field in China.
The company, formerly known as Luoyang Bearing Factory founded in 1954, was one of the 156 key construction projects during China's "Fifth Five-Year Plan" period. With prominent R&D capabilities and technological innovation, the company has broken foreign monopolies and achieved localization in many high-end bearing fields such as major equipment and high-end equipment. The company's products have been assessed by the China Bearing Industry Association to have reached international leading or advanced levels in many technological achievements. The company's R&D focuses on national strategic needs, undertaking various national scientific research tasks, being one of the first companies in China to conduct research on high-speed EMU bearings or high-speed train bearings, and undertaking research and development tasks for the main spindle bearings of C919 and C929 domestic aircraft engines.
The company's product series includes over 30,000 types, ranging in size from 6mm inner diameter to 15m outer diameter, widely used in major equipment, high-end equipment, and strategic emerging industries such as new energy vehicles.
According to data from the China Bearing Industry Association, the issuer's bearing products ranked fourth in domestic bearing industry revenue from 2023 to 2024. The company's products mainly focus on special bearings, with a relatively high proportion of major equipment bearings, high-end equipment bearings, and new energy vehicle bearings. According to the certification documents issued by the China Bearing Industry Association, in 2024, the company's major equipment bearings ranked first in the industry in wind power main shaft bearings, wind power pitch bearings, and wind power gearbox bearings; high-end equipment bearings ranked top three in the industry in rail transit bearings and aerospace bearings; and automotive bearings ranked top three in the industry in new energy vehicle hub bearings.
Financially, in 2023, 2024, and 2025, the company achieved operating revenues of approximately 4.41 billion yuan, 4.675 billion yuan, and 6.034 billion yuan, respectively; during the same period, the company's net profits were approximately 2.36 billion yuan, 2.47 billion yuan, and 5.44 billion yuan, respectively.
Related Articles

Dohua Jixian: Raised BEKE-W (02423) target price to HK$53, upgraded to "Buy" rating

HK Stock Market Move | SKB BIO (06990) rose by over 5%, reaching the major endpoint of the global Phase III study of TROP2 ADC in collaboration with Merck.

HK Stock Market Move | ASCLETIS-B(01672) rose over 5% in early trading with GIC's shareholding ratio increasing to 7%. ASC30 US Phase II study has completed enrollment.
Dohua Jixian: Raised BEKE-W (02423) target price to HK$53, upgraded to "Buy" rating

HK Stock Market Move | SKB BIO (06990) rose by over 5%, reaching the major endpoint of the global Phase III study of TROP2 ADC in collaboration with Merck.

HK Stock Market Move | ASCLETIS-B(01672) rose over 5% in early trading with GIC's shareholding ratio increasing to 7%. ASC30 US Phase II study has completed enrollment.






